DARA Biosciences — Q3 2013 Earnings Presentation
16 slides from DARA Biosciences's earnings presentation, Nov 14, 2013
Slide 1: Q3 2013 Financial Results and Corporate Business Update
NASDAQ: DARA www.darabio.com Q3 2013 Financial Results and Corporate Business Update Conference Call and Webcast November 14, 2013
Slide 2: Forward Looking Statements
Page * Page * Forward Looking Statements All statements in this presentation that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended , and are subject to risks and uncertainties. These statements are based on the current expectatio
Slide 3: Opening Comments
Opening Comments David Drutz, MD, CEO & CMO
Slide 4: DARA's goal is to establish a leadership position in oncology supportive care
DARA’s goal is to establish a leadership position in oncology supportive care q Oncology supportive care is an attractive area of focus and uniquely positions DARA q Refined commercial focus has yielded encouraging sales q Sales force expansion and new product opportunities setting the stage for gro
Slide 5: Q3 Oncology Supportive Care
Q3 Oncology Supportive Care Product Portfolio Review and Recent Events Chris Clement, President & COO
Slide 6: Oncology supportive care focus is a differentiating factor for DARA
Oncology supportive care focus is a differentiating factor for DARA in the market q Significant opportunity / unmet medical need q Competitive products not optimal q Limited existing therapeutic options q Portfolio approach q Synergy creates opportunity q Potential for increased access to caregivers
Slide 7: Q3 commercial/sales efforts significantly increased focus on high prescribing oncologists
Q3 commercial/sales efforts significantly increased focus on high prescribing oncologists/radiologists (reach/frequency) q Encouraging sales results • Strong increase in Rx growth for Soltamox® (1) and Gelclair® ( 2 ) q Positive performance indicators for continued growth • Increased formulary place
Slide 8: January 1, 2014 we will have full national coverage with sales representatives
January 1, 2014 we will have full national coverage with 20 sales representatives Sales Force
Slide 9: Strategic Partnership: Mission Pharmacal/Alamo
Mission is a privately-held pharmaceutical company (750 employees) manufacturing and selling branded and consumer products WW Strategic Partnership: Mission Pharmacal/Alamo q Alamo is a wholly-owned subsidiary • Experienced CSO (Contract Sales Organization) • Full service provider o SFA/Infrastructu
Slide 10: Partnership with ALAMO/Mission facilitates a comprehensive oncology supportive care portfolio
Partnership with ALAMO/Mission facilitates creation of a comprehensive oncology supportive care portfolio Page * Osteoporosis Anemia Oral mucositis Dry mouth CCIPN* * Phase 2b - ready drug (KRN5500). Chronic chemotherapy induced peripheral neuropathy (CCIPN) Comprehensive Portfolio Dermatitis
Slide 11: DARA can leverage its newly established portfolio of oncology supportive care products
DARA can leverage its newly established portfolio of oncology supportive care products* Page * Synergy Creation Breast cancer patient (illustrative) • Soltamox® • Bionect® (1) • Gelclair® • Ferralet® 90 * • Binosto® * • Aquoral® * ─ Breast cancer (1) Full prescribing information is available at www.
Slide 12: Oncology Supportive Care provides DARA a unique opportunity to create shareholder value
Oncology Supportive Care provides DARA a unique opportunity to create near-term and sustained shareholder value Oncology Supportive Care q Providing products meeting market need q Capitalize on product synergy/portfolio selling q Opportunity to expand product offerings q KRN-5500 addressing an area
Slide 13: Q3 Financial Summary
Q3 Financial Summary Dave Tousley, CFO
Slide 14: Closing Comments
Closing Comments David Drutz, CEO & CMO
Slide 15: DARA has significant potential for near and long term value creation
DARA has significant potential for near and long term value creation and revenue growth Poised for an exciting 2014 q Unique strategic positioning with a portfolio of synergistic oncology supportive care products q Expanded sales force with an experienced/successful CSO • Revenue growth q Novel phas
Slide 16: Q3 2013 Financial Results and Corporate Business Update
NASDAQ: DARA www.darabio.com Q3 2013 Financial Results and Corporate Business Update Conference Call and Webcast Rev. 1113